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Abstract
Onychomycosis is a common fungal infection affecting nails. The infection is 
frequently due to dermatophyte, while yeast and non-dermatophyte molds (NDMs) 
attributed especially in immunocompromised patients. NDMs and Candida species 
can be involved as primary or secondary pathogens. Candida onychomycosis (CO), 
most commonly caused by C. albicans and C. parapsilosis, is frequently associated 
with local or systemic immune disturbances. In the cases that the host immunity 
is severely affected, Candida acts as primary pathogen, while other diseases e.g., 
diabetes mellitus, malnutrition, and smoking serve as predisposing factors for 
Candida to cause secondary infection. Furthermore, formation of biofilms and 
production of enzymes contribute as the virulence factors of the yeasts. Clinical 
manifestation of CO varies, from discoloration and marked thickening of the nail to 
dystrophic nails with fingernails more commonly affected. Paronychia is the most 
common type of CO and Candida granuloma is one of the severe types of CO which 
often occurs in chronic mucocutaneous candidiasis. Establishing the diagnosis of 
CO is crucial as well as the identification of each predisposing factors. Microscopic 
examination and fungal cultures are the gold standard examination for diagnosing 
onychomycosis, while for NDM, multiple confirmation and repeated examination is 
needed due to its as contaminants.
Keywords: candida onychomycosis, nail, fungal infection, diagnostic challenges, 
treatment
1. Introduction
Onychomycosis is a common nail infection caused by fungi, namely yeasts, 
dermatophytes, and non-dermatophyte molds (NDMs) [1]. The prevalence 
keeps increasing with age and it is commonly identified in elderly populations. 
Approximately 20% of adults in their second to fourth decades are affected by this 
disease. Yeasts contribute to 24–50% cases of onychomycosis with Candida species 
as the most common agent [2]. Various factors are associated with the event of 
onychomycosis, e.g. host’s comorbidities (human immunodeficiency virus [HIV] 
infection, diabetes mellitus, peripheral circulation disturbances), repeated nail 
trauma, smoking, antibiotic therapy, immunosuppressive therapy, repeated expo-
sure to fungi, humid climates, genetic predisposition, and occlusive footwear [2, 3]. 
Establishing the diagnosis of Candida onychomycosis (CO) is challenging. Albeit 
frequently identified in culture and direct microscopic examination, the presence 
of Candida species might only be colonization, not necessarily the cause of nail 
diseases. A careful interpretation of diagnostic tests’ results and correlation with 
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results of clinical examination are necessary to establish the diagnosis of CO which 
will aid the clinicians in providing correct treatment for the patients [4].
2. Epidemiology
The prevalence of onychomycosis differs based on geographical location with 
worldwide prevalence of approximately 10% [5]. The incidence onychomycosis in 
North America ranges from 8.7–13.8% while the prevalence in Southeast Asia ranges 
from 2–6% [2, 3]. Higher prevalence is reported in countries with humid climates, 
such as Greece (27.99%) and Ethiopia (60,4%), [6, 7] While there are three groups 
of fungi responsible for onychomycosis, dermatophytes are the most common cause 
of onychomycosis (60–70%) [3].
Yeasts, most commonly identified as Candida species in onychomycosis, con-
tributes in approximately 40% of the onychomycosis cases in Southeast Asia. Other 
studies reported that the prevalence of CO varies between 24–50% of onychomyco-
sis cases [2]. NDMs and yeasts onychomycosis is more common in subtropical and 
tropical climates while dermatophytes is more common in temperate climates [7]. 
Candida albicans is identified as the most common isolated species, followed by C. 
parapsilosis, C. krusei, C. tropicalis, and C. glabrata [2]. CO is more frequently to be 
identified in fingernails than toenails, especially in patients with hands continu-
ously immersed in water [3].
3. Prognostic factors
In assessing the treatment outcome of CO patients, there are three types of cure 
to be considered, which area mycological cure, clinical cure, and complete cure. 
Clinical cure is described as a previously infected nail without signs and symptoms 
of onychomycosis. Mycological cure is described as negative results on both direct 
microscopic examination and culture. Complete cure is described as achieving both 
clinical and mycological cure [8]. Various prognostic factors have been identified 
for the treatment outcome of onychomycosis. In general, they can be divided into 
three groups, which are patient’s characteristics, nail features, and the infectious 
agents (Table 1) [9].
Most studies reported that the onychomycosis is more commonly diagnosed in 
men. Male patients are associated with poor outcome because they are more likely to 
be exposed to repeated nail trauma and they usually do not seek health care until the 
disease becomes too advanced. Furthermore, they are more likely to have low com-
pliance; hence, male patients become more resilient when it comes to treatment and 
have 2,6 times risk of not achieving clinical cure [8]. Increasing age is also known to 
be associated with poor prognosis in onychomycosis patients because elderly popula-
tions usually suffer from poor circulation system, poor immune status, decreased 
nail growth, and mixed fungal infections. Hence, their response to therapy might be 
lacking and they have 3,7 times risk of not achieving clinical cure [8, 9].
Nail trauma can exert significant and irreversible damage which will predispose 
patients to onychomycosis. Patients who have abnormal nails with positive mycol-
ogy examination had 5,4 times risk of developing onychomycosis [9]. Other poor 
prognostic factor is history of onychomycosis. Patients with prior infection have 
2,3 times risk of not achieving clinical cure. These patients are more likely not to 
respond standard treatment course since they have been treated before. There 
might also be involvement of genetic susceptibility in the development of recurrent 
onychomycosis [8].
3
Book Chapter Candida Onychomycosis: Mini Review
DOI: http://dx.doi.org/10.5772/intechopen.96650
As most fungi are opportunistic agents, poor immune status can predispose 
patients to onychomycosis, especially in HIV patients with CD4 count <400/mm3. 
The onychomycosis is more likely to involve fingernails and toenails also more 
severe [9]. Patients with hand and foot involvement have 1.1 times risk of not 
achieving complete cure and if the patients have more than 3 infected nails, they 
have 1.5 times risk of not achieving complete cure [4]. Furthermore, hallux involve-
ment presents as poor prognostic sign because it is more likely to suffer repeated 
trauma lead to predisposition of continuous infection.
In addition, poor peripheral circulation caused by chronic venous disease is associ-
ated with poor prognosis. Chronic venous disease can cause nail dystrophy, hyperkera-
tosis, discoloration, hyperplastic nail bed, and onychogryphosis. Only 25% of patients 
treated with itraconazole are cured [9]. Poor peripheral circulation can also identified 
in patients with uncontrolled diabetes mellitus which associates with secondary 
infections and nonhealing ulcers. This population is also reported to have more severe 
onychomycosis, high recurrence rate and longer duration to achieve complete cure [9].
Poor Prognostic Factors
Patient’s characteristics Male gender
Increasing age





Repeated exposure to water and detergents
Repeated exposure to mud and soil
Barefoot walking
Nail features Subungual hyperkeratosis >2 mm
Fingernail and toenail involvement















Poor prognostic factors in onychomycosis [4, 8–10].
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Repeated exposure to water and detergents will predispose patients to chronic 
paronychia and affect the drug delivery since the tissue is more edematous and 
inflamed. While repeated exposure to mud and soil, also barefoot walking will 
predispose the patients to repeated minor trauma. Most fungi are saprophytic; 
hence, they can invade nails easily in this condition. This often happened in tropical 
countries [10].
Subungual hyperkeratosis is host’s reaction towards fungal infection by thick-
ening the stratum corneum. The thick debris presents as a barrier to antifungal 
agents, both systemic and topical agents [9]. Furthermore, patients with matrix 
involvement have 2.1 times risk of not achieving complete cure [8]. Matrix is known 
to be the nail’s origin [11]. Hence, matrix involvement in onychomycosis will affect 
the nail growth and drug delivery [8]. In addition, the slow nail growth is also a 
poor prognostic factor since the patients shed the infected portion of the nail more 
slowly. This association is also described in elderly populations. Slow nail growth is 
also seen in significant nail plate involvement. Greater surface involved is associated 
with greater fungi load; hence, lower cure rates [9].
Significant lateral disease affects the treatment outcome since there is poor 
attachment of the lateral edge to the nail groove. This can reduce the drug delivery 
about two thirds of normal nail. Similar cases are seen in severe onycholysis [9]. 
Patients with lateral disease have 3,5 times risk of not achieving complete cure [8]. 
Another poor prognostic factor is dermatophytoma, a dense thick-walled fungal 
elements presenting as white to yellow patch or longitudinal streak in nail plate. 
This dense mass is difficult to be penetrated by antifungal agents. Therefore, 
the patients with dermatophytoma have 2.9 times risk of not achieving clinical 
cure [8, 9].
Melanonychia is black pigmentation identified on the nail plate. This feature is 
associated with poor prognosis in onychomycosis. However, the association has not 
been elucidated yet. Total dystrophic onychomycosis (TDO) is the final destructive 
stage of onychomycosis, in which there is thickened nail bed, crumbling nail plate, 
and significant involvement of nail matrix. Patients with TDO have 1.1 times risk of 
not achieving complete cure [4, 9].
As for the infectious agents, CO and NDMs onychomycosis indicate poor 
prognosis. CO is associated with immunosuppression, especially in case of chronic 
mucocutaneous candidiasis (CMC) and HIV patients. While NDMs infections are 
difficult to be diagnosed and lack of data for treatment course. In addition, fungal 
and bacterial infections can complicate the treatment. Therefore, these factors can 
implicate in poor prognosis of onychomycosis patients [9].
In order to aid the clinicians in have better treatment outcome, several instru-
ments have been developed to predict the prognosis in onychomycosis patients. The 
first developed instrument was Scoring Clinical Index for Onychomycosis (SCIO 
Index). This scoring assesses the nail’s clinical component based on its clinical 
form, nail involvement, and subungual hyperkeratosis. In addition, it assesses the 
growth component based on the patient’s age and location of onychomycosis. As the 
score increases, the onychomycosis might be more difficult to treat [12]. However, 
this scoring has not been validated and has other limitations, such as exclusion of 
important prognostic factors and complex calculation [9].
Another scoring was developed by Baran et al. (Table 2). The higher the score, 
the more likely the treatment failure will happen [13]. Albeit being the most com-
prehensive instrument, this index has not been validated and time-consuming [9].
The most commonly used instrument is Onychomycosis Severity Index (OSI). 
OSI is simpler by assessing three major components, which are area of involve-
ment, proximity of disease to matrix, presence of dermatophytoma or subungual 
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hyperkeratosis >2 mm (Table 3). The score is multiplication of score for area of 
involvement with score for proximity of disease and addition of score for the pres-
ence of dermatophytoma or subungual hyperkeratosis >2 mm. Score 1–5 indicates 
mild onychomycosis; 6–15 indicates moderate onychomycosis; and 16–35 indicates 
severe onychomycosis [14]. This index has been validated with high reliability. 
However, this index only assesses one nail, does not correlate the severity of disease 
with treatment outcome, and excludes other important prognostic factor [9].
Descriptor Subdivision Score
1 Extent of involvement Distal one-third of nail plate 1
Distal two-thirds of nail plate 2
Proximal nail plate involvement 3
2 Diffuse nail plate thickening Mild or moderate 1
Associate with onychogryphosis 3
3 Nail plate thickening associated with the 
appearance of linear streaks – includes the 
change confined to the lateral border
One streak only 2
Two or more streaks 3
If the streaks are black do not score but 
see 7
4 Onycholysis Affecting the distal two-thirds of nail 
plate
2
5 Location Any one of:
Second to fifth toes or thumb 1
Great toenail 2
6 Paronychia associated with nail plate disease With diffuse melanonychia 3
With melanonychia at the lateral edges 
of the nail
3
7 Melanonychia (without paronychia) With one or more longitudinal streaks 3
Diffuse pigmentation 4




9 Presence of the following predisposing factors Diabetes mellitus 1
Known severe trauma to affected nail 2
Immunosuppression (due to therapy, e.g., 
prednisolone, or disease, e.g., AIDS)
4
Symptomatic peripheral vascular disease 2
10 Causative organism Scytalidium spp. 4
Other mold fungi 2
Yeasts 1
Cited as is from Baran et al. [13].
Table 2. 
Baran-Hay’s severity index for onychomycosis [13].
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4. Pathogenesis and causative agent
The most common causative agent of yeast onychomycosis is candida species. 
Fingernails are the predilection site of CO, especially in patients who are regularly 
submerging their hands in water [3]. Candida species are a commensal part of the 
normal skin flora, which are present in nature. However, these species may exhibit 
opportunistic quality in an immunocompromised host. Candida species can be 
either primary or secondary causative agent in onychomycosis. Primary CO can be 
commonly encountered in a severe immunocompromised host, for example, in HIV 
patient. On the contrary, secondary CO is usually related to predisposing diseases 
or circumstances, for instance, diabetes mellitus, malnutrition, peripheral vascular 
disease, chronic nail trauma, smoking, and vulnerable age (elderly and children). 
Particular occupations such as housekeepers, fishers, and farmers are also at risk 
of CO due to the frequent trauma and excessive moisture on the nails, exposure to 
contaminants, and contact with chemicals [2].
Instead of appearing as individual spores and hyphae, fungal organisms tend to 
integrate, forming a biofilm which is a syntrophic group of fungi adhering to the 
host’s surface. When not infiltrating a substrate, fungi may fluctuate between free-
floating types and parts of a superficial biofilm. This particular feature provides 
benefits for fungi development while being surrounded by extracellular matrix 
(ECM). The surrounding ECM defends fungi from the host’s immune response 
and antifungal treatments. ECM also supports fungi to distribute nutrients to the 
biofilm. Fungi biofilm contributes to the rationale of why onychomycosis is rela-
tively refractory to antifungal treatment and challenging to eliminate the spores in 
chronic manifestation entirely [3].
The biofilm development by C. albicans is initially started with the adhesion 
and colonization of C. albicans cells on an appropriate substrate. Several features 
that influence the attachment process of C. albicans are non-specific factors (elec-
trostatic forces and hydrophobic part of the cell membrane) and specific factors 
(adhesin on the extracellular layer of C. albicans, which connects the ligands on 
Predictor Subdivision Score











Presence of dermatophytoma or subungual hyperkeratosis >2 mm No 0
Yes 10
Cited as is from Carney et al. [14].
Table 3. 
Onychomycosis severity index [14].
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the film). Besides attaching to their counterparts, Candida species can also occur 
secondary to bacteria that have previously colonized their host. When the attach-
ment process followed by microcolonies formation has completed, C. albicans 
began to proliferate characterized by the budding yeasts, production of filamentous 
structure, and deposition of ECM materials, ultimately resulting in biofilm forma-
tion. The filamentous structure supports the biofilm scaffolding and protects the 
adhesion spots for the budding yeasts [15].
There are 3 definite stages of C. albicans observed through microscopic exami-
nation, including early stage (0–11 hours), intermediate stage (12–30 hours), and 
maturation stage (72 hours) [15, 16]. During the 3rd and 4th hour, budding yeasts’ 
microcolonies can be observed, while pseudo-hyphae and true hyphae start to 
appear in the 4th hour and 8th hour, respectively. Throughout the intermediate 
stage, microcolonies are later bounded by hyphae, which eventually results a single 
coalescent layer formation. An opaque film overlaying the microcolonies can be 
observed at this stage, which is mainly composed of non-cellular material such as 
polysaccharides. The basal layer is composed of yeast cells, while the filamentous 
cells constitute the underlying structure. Eventually, the maturation stage is charac-
terized by the multiplication of extracellular material in a time-dependent manner 
until the mature biofilm covering the entire fungi has been developed [15].
In addition to biofilm, yeast factors that contribute to the virulency of CO 
are synthetization of hydrolytic enzymes, including proteinase, hemolysin, and 
phospholipase, which are unique between each type of Candida species. Moreover, 
proteinase plays a part in the breakdown of protein and phospholipase contributes 
to the destruction of the host cell, allowing Candida species to invade the host [2]. 
The reported prevalence of CO is 5–10% of all onychomycosis cases. The most com-
mon causative species of CO are C. albicans and C. parapsilosis [17].
5.  Clinical presentation in immunocompetent and immunocompromised 
patients
Most CO cases involve fingernails compared to toenails, with an estimated 
prevalence of up to 50% of onychomycosis cases in fingernails. Women at risk of 
developing CO are typically wet workers due to the recurrent moist in the hands, 
exposure to trauma, regular contact with washing liquids, and contamination to 
vaginal flora during cleansing, which ultimately provides a suitable niche for the 
development of Candida species [2].
Clinical presentations that are predictive for CO are nail plate dystrophy and 
off-white discoloration, commonly followed by pigmentation. Melanisation, one of 
the virulence factors for Candida, suggests an indication of progressive resistance 
to antifungal treatment. Classification of CO is established because of the complex 
etiopathogenesis and diverse clinical presentations. The first clinical classifica-
tion of CO was suggested based on the clinical presentation, the affected location, 
and the infection route, which are Candida paronychia, Candida granuloma, and 
Candida onycholysis [2].
The most frequent type of CO is paronychia. Humidity plays an essential role 
in the development of Candida paronychia. Clinical manifestation of Candida 
paronychia comprises erythema and swelling in the nail folds followed by gradual 
dystrophy in the nail plate accompanied by paronychia and Beau lines, which is 
depicted by an oblique dent in the nail plate suggesting parasite infestation on 
the nail matrix. The most severe type of CO is granuloma, which is frequently 
observed in patients with chronic mucocutaneous candidosis. Clinical manifesta-
tion of Candida granuloma displays brittle nails and a deformity resembling 
Candida albicans
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drumstick which is also referred to as pseudoclubbing. The last type of CO is 
onycholysis. Clinical manifestation of Candida onycholysis is characterized by 
subungual distal hyperkeratosis, which further develops into a group of kerato-
sis separating the nail plate from the bed. Moreover, a recent classification was 
proposed, including four clinical groups of CO, which are chronic paronychia with 
secondary nail dystrophy, distal onychomycosis, chronic mucocutaneous  
candidosis, and secondary candidosis [17].
Chronic paronychia initially emerges from the proximal nail fold, although lat-
eral nail folds are occasionally affected in the beginning. Swelling of the periungual 
skin and a noticeable gap between the fold and nail plate is observed, followed by 
the nail plate involvement. Marks with a white, green, or black color can be detected 
at the lateral and distal parts, respectively. The longitudinal ridges and opaqueness 
appear on the nail that develops into a brittle and easily detached nail. Pressure 
and movement on the nail can be painful in contrast to dermatophyte infections. 
A superimposed infection caused by bacteria into the subcuticular space usually 
occurs, leading to a vicious cycle. Chronic paronychia usually appears in adults 
whose occupations regularly contact water and children because of the thumb  
sucking habit [17].
Distal candida nail infection manifests as subungual hyperkeratosis along with 
onycholysis. Differentiating the clinical manifestation with dermatophytosis can be 
challenging, however the candida results in less extent damage to the nail compared 
to dermatophyte. In addition, the predilection of CO usually affects the fingernails, 
while most dermatophytes invade the toenails. The prevalence of distal candida nail 
infection is infrequent and most of the cases are related to vascular problems, such 
as Raynaud’s phenomenon [17].
Total dystrophic onychomycosis occurs in patients with chronic mucocutaneous 
candidosis. The organism invasion on the nail plate results in hyperkeratotic and 
gross thickening of the nail. Chronic mucocutaneous candidosis has multifaceted 
etiology which results in the weakened cell-mediated immunity. The variety of 
clinical appearance depends on the severity of immunosuppression; however, thick-
ening of the nails can be observed in advanced cases due to the Candida granuloma. 
In addition, the involvement of the mucous membrane is nearly presented in most 
cases [17].
Secondary candida onychomycosis results because of other diseases involving 
the nail apparatus, most commonly psoriasis [17].
6. Diagnostic tests
Common tests utilized in the diagnosis of onychomycosis are potassium 
hydroxide (KOH) preparation, fungal culture, histopathology, polymerase chain 
reaction (PCR), and flow cytometry (Table 4). The combination tests are usually 
performed; however, the gold standard of diagnostic tests are microscopy and 
culture [3].
Onychoscopy can also be used for initial diagnosis of onychomycosis. The most 
common findings in onychomycosis are jagged edge with spikes of the proximal 
part of the onycholysis, parallel bands of various color resembling aurora borealis 
pattern, and ruin appearance at the subungual part [3].
KOH microscopy and fungal culture are presently the gold standards to establish 
the diagnosis of onychomycosis. However, it remains questionable because KOH 
microscopy demonstrates a false-negative rate between 5% to 15% and false-
positive for evaluating the medication, given that KOH microscopy visualizes both 
live and dead hyphae which are identical through microscope. Furthermore, fungal 
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culture has a wide-ranging sensitivity from 30% to 57% and requires incubation for 
weeks. Latest studies comparing a variety of diagnostic tests indicate that histopa-
thology staining has higher sensitivity than KOH microscopy or culture, although 
another study suggests PCR for a quicker and precise alternative for fungal culture, 
particularly in NDM onychomycosis. Therefore, the combination of diagnostic tests 
is recommended to diagnosis onychomycosis accurately. A feasible option can be 
a KOH microscopy and PCR (or culture in a resource-limited setting) if the KOH 
shows positive results [3].
In the case of CO, obtaining sample for KOH microscopy and culture can be 
performed from the proximal and lateral parts of the nail. Nevertheless, sample can 
be obtained from the distal part in the case of onycholysis. Culture result may reveal 
creamy-whitish colonies on Sabouraud dextrose agar media or primary isolation can 
also be attained using chromogenic media, for instance CHROMagar Candida®. 
Anti-fungal susceptibility should be performed following the identification of the 
isolated strains to achieve the most effective therapy. Histopathological results of 
CO usually display hyphae and pseudomycelia on the nail through Schiff ’s periodic 







keratinocytes result in 
the flattening of nail 
segment and decreasing 
reflection from cell 








Fungal culture Cleaned and clipped 
subungual debris of the 
nail are scraped into the 
gauze. Culture developed 










Histopathology Stained by hematoxylin 
and eosin to depict the 
elements of the fungi. 
Periodic acid-Schiff or 
Grocott’s methenamine-
silver can be utilized to 











PCR Employ a target gene part 







Flow cytometry Employ granulosity, 
cell volume, DNA, 
and protein markers to 








Cited as is from Gupta et al. [3].
Table 4. 
Diagnostic tests for onychomycosis [3].
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acid stains or Grocott’s methenamine silver stains. PCR can also be utilized for 
further identification [2].
7. Treatment algorithm
Defining the resolution of onychomycosis can be achieved through clinical, 
mycological, and complete cure. Clinical cure is described as 100% improvement 
depicted by clear nail, while mycological cure is described as negative KOH micros-
copy and negative fungal culture, respectively. Ultimately, complete cure comprises 
100% clear nail and mycological cure. The goal of treating onychomycosis for 
physicians and affected stakeholders are achieving the complete cure. However, it 
is difficult for an infected nail to return into an utterly normal appearance, particu-
larly in advanced stage although mycological cure has been attained [3].
The treatment choices (Figure 1) available for managing onychomycosis are oral 
medication, topical therapy, and devices. Oral antifungals (Table 5) are the first-
line therapy because they result in high success rates. Nevertheless, oral antifungals 
are contraindicated in patients with chronic or active liver disease, congestive 
heart failure, and kidney failure. Besides, oral antifungals may interact with 
other pharmacological agents, which can trigger a severe adverse reaction. These 
setbacks urged the request for the safer option which leads to the awareness of 
topical therapy. Topical treatments (Table 6) are indicated in mild–moderate cases 
and patients with contraindication for oral antifungals. However, they also have 
limitations which are smaller cure rate, prolonged therapy and difficulty applying 
for patients with mobility problems. Ultimately, lasers are FDA-approved device 
therapy for short-term clearance and/or nail enhancement. However, laser therapy 
is lacking conclusive guidance and its efficacy demonstrates notable disparities 
among all treatment modalities. Topical antifungals eradicate the fungus from the 
outward penetrating the dorsal part of the nail, whereas oral antifungals eliminate 
from the inward infiltrating the ventral part of the nail [3].
Another proposed treatment algorithm is based on the severity of onychomyco-
sis assessed with SCIO (Table 7) [12].
Figure 1. 
Treatment algorithm of onychomycosis [16]. Cited as is from Christenson et al. [16].
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Drug name Terbinafine Itraconazole Fluconazole



























NDMs, and Candida 
spp.
Dermatophytes, 
some NDMs, and 
Candida spp.
Efficacy MC 70% 54% 47–62%
CC 38% 14% 28–36%*
Approval US–1996 US–1995 US–1990†
EU–1991 EU–1989 EU (UK)–1988







CYP, cytochrome P450; NDM, non-dermatophyte molds; MC, mycological cure; CC, complete cure.
*Data provided are clinical cure rates.
†Fluconazole was FDA-approved for use in humans in 1990, but is not yet approved for treatment of onychomycosis 
in the US or Canada.
Cited as is from Gupta et al. [3].
Table 5. 
Summary of available oral antifungal [3].
Drug name Efinaconazole Tavaborole Ciclopirox Amorolfine
Trade name Jublia Kerydin Penlac Loceryl
Chemical 
structure
Triazole Oxaborole Hydroxypyridone Morpholine
Molecular 
formula
C18H22F2N4O C7H6BFO2 C14H24N2O3 C21H35NO




































8. Prevention and education
As CO commonly recurs with overall onychomycosis recurrence rate of 10–53%, 
additional measures should be implemented to prevent this recurrence. For the 
clinicians, it is imperative to confirm the diagnosis and identify the infectious agent 
before providing treatment. Assessing and treating the comorbidities is also crucial 
since some comorbidities are risk factors for onychomycosis, also portend as poor 
prognostic factors. Tinea pedis should be treated properly as the infected skin can 
play a role as reservoir for the pathogens [3].
When the patients are diagnosed, the clinicians should provide them with opti-
mal onychomycosis therapy, provide counseling on the expectations and adherence 
to treatment. The patients should also be provided with information to maintain 
hand and foot hygiene, avoid occlusive shoes, trim the nails regularly, use broad 
toed shoes with absorbent materials, and avoid barefoot walking in locations with 
SCIO Treatment approach
1–3 Topical treatment: remove (cut or scrape off) affected marginal parts of the nail
Use topical antifungals until healthy nail regrows
3–6 Topical treatment with lower success, which often depends on growth rate
Systemic therapy recommended in slower-growing nails or proximal onychomycosis type
6–9 Systemic therapy. Use scheme proposed for fingernails (e.g., itraconazole: 2 pulses of 200 mg bid)
9–12 Systemic therapy. Use scheme proposed for toenails (e.g., itraconazole: 3 pulses of 200 mg bid)
12–16 Systemic therapy. Use scheme proposed for fingernails with any antifungal (e.g., 4–5 pulses of 
itraconazole, 200 mg bid)
16–20 Combination therapy (systemic antifungal + topical measures)
Adequate keratolytic treatment recommended
20–30 Consider nail avulsion (e.g., with urea paste), continue with systemic therapy
Cited as is from Sergeev et al. [12].
Table 7. 
Proposed treatment approach based on scoring clinical index of onychomycosis (SCIO) [12].
Drug name Efinaconazole Tavaborole Ciclopirox Amorolfine
Efficacy MC 53.4–55.3% 31.1–35.9% 29–36% 60%125
CC 15.2–18.8122 6.5–9.1%121 5.5–8.5%123






C C B Poor systemic 
absorption, 
safe in animals, 
no studies in 
pregnant women†
CC, complete cure; MC, mycological cure; NDM, non-dermatophyte molds.
†Not approved by FDA, thus no pregnancy classification.
Cited as is from Gupta et al. [3].
Table 6. 
Summary of available topical antifungal [3].
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abundant fungal density (e.g., swimming pool, communal showers, gymnasium 
floors). Good sanitization measures should be taken for previous infected socks 
and shoes. Socks should be washed with hot water (60 °C) for 45 minutes and shoes 
should be exposed to ultraviolet rays or ozone or can be sprayed with antifungal 
sprays. The close contacts or family members of the patients should be examined 
and treated if they suffer from onychomycosis or tinea pedis [3, 18].
Prophylaxis can be considered for patients with high probability to suffer from 
recurrence. Topical antifungal agent in the form of solution or lacquer can be 
applied once daily for a month then twice weekly for at least two years after the cure 
have been achieved [3].
9. Conclusions
CO is a common nail infection affecting people worldwide. Establishing the 
diagnosis of CO becomes a challenge for the clinicians since Candida spp. is a 
well-known normal flora inhabiting human’s skin, nails and mucosa. In addition 
to confirming the diagnosis, the clinicians should pay attention to patient’s charac-
teristics, nail features, and the infectious agent as it can portend as poor prognostic 
factors. A proper treatment course along with additional measures will aid the 
patient to achieve complete cure and prevent recurrence.
Conflict of interest




CMC Chronic Mucocutaneous Candidiasis
CO Candida Onychomycosis
HIV Human Immunodeficiency Virus
KOH potassium hydroxide
NDMs Non-Dermatophyte Molds
PCR Polymerase Chain Reaction
SCIO Scoring Clinical Index of Onychomycosis




Sandra Widaty*, Eliza Miranda and Caroline Oktarina
Department of Dermatology and Venereology, Faculty of Medicine Universitas 
Indonesia-dr. Cipto Mangunkusumo National Central General Hospital, Jakarta, 
Indonesia
*Address all correspondence to: sandra.widaty@gmail.com
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Book Chapter Candida Onychomycosis: Mini Review
DOI: http://dx.doi.org/10.5772/intechopen.96650
References
[1] Gupta AK, Versteeg SG, Shear NH. 
Onychomycosis in the 21st Century: An 
Update on Diagnosis, Epidemiology, 
and Treatment. J Cutan Med Surg. 
2017;21(6):525-39.
[2] Andrés T-S, Alexandro B. candida 
Onychomycosis: an Old Problem 
in Modern Times. Current Fungal 
Infection Reports. 2020;14(3):209-16.
[3] Gupta AK, Stec N, Summerbell RC, 
Shear NH, Piguet V, Tosti A, et al. 
Onychomycosis: a review. J Eur Acad 
Dermatol Venereol. 2020;34(9):1972-90.
[4] Widaty S, Miranda E, Bramono K, 
Menaldi SL, Marissa M, Oktarina C, et 
al. Prognostic factors influencing the 
treatment outcome of onychomycosis 
Candida. Mycoses. 2020;63(1):71-7.
[5] Gupta AK, Taborda VBA,  
Taborda PRO, Shemer A, 
Summerbell RC, Nakrieko KA. High 
prevalence of mixed infections in 
global onychomycosis. PLoS One. 
2020;15(9):e0239648.
[6] Bitew A, Wolde S. Prevalence, Risk 
Factors, and Spectrum of Fungi in 
Patients with Onychomycosis in Addis 
Ababa, Ethiopia: A Prospective Study. J 
Trop Med. 2019;2019:3652634.
[7] Gregoriou S, Mpali N, Vrioni G,  
Hatzidimitriou E, Chryssou SE,  
Rigopoulos D. Epidemiology of 
Onychomycosis in an Academic Nail 
Unit in South Greece during a Three-
Year Period. Skin Appendage Disord. 
2020;6(2):102-7.
[8] Sigurgeirsson B. Prognostic factors 
for cure following treatment of 
onychomycosis. J Eur Acad Dermatol 
Venereol. 2010;24(6):679-84.
[9] Lipner SR. Prognostic Factors in 
Onychomycosis Treatment. Journal 
of Infectious Diseases and Therapy. 
2014;03(01).
[10] Ranawaka RR, de Silva SH. 
Factors influencing cure rates of non-
dermatophyte mold and Candida 
onychomycosis: analysis of outcomes in 
81 patients who completed treatment. 
Int J Dermatol. 2017;56(2):202-8.
[11] de Berker D. Nail anatomy. Clin 
Dermatol. 2013;31(5):509-15.
[12] Sergeev AY, Gupta AK, 
Sergeev YV. The Scoring Clinical Index 
for Onychomycosis (SCIO index). Skin 
therapy letter. 2002;7 Suppl 1:6-7.
[13] Baran R, Hay RJ, Garduno JI. Review 
of antifungal therapy and the severity 
index for assessing onychomycosis: part 
I. J Dermatolog Treat. 2008;19(2):72-81.
[14] Carney C, Tosti A, Daniel R, 
Scher R, Rich P, DeCoster J, et al. A 
new classification system for grading 
the severity of onychomycosis: 
Onychomycosis Severity Index. Archives 
of dermatology. 2011;147(11):1277-82.
[15] Ramage G, Mowat E, Jones B, 
Williams C, Lopez-Ribot J. Our current 
understanding of fungal biofilms. 
Critical reviews in microbiology. 
2009;35(4):340-55.
[16] Chandra J, Kuhn DM, 
Mukherjee PK, Hoyer LL, McCormick T, 
Ghannoum MA. Biofilm formation by 
the fungal pathogen Candida albicans: 
development, architecture, and drug 
resistance. Journal of bacteriology. 
2001;183(18):5385-94.
[17] Ameen M, Lear JT, Madan V, 
Mohd Mustapa MF, Richardson M. 
British Association of Dermatologists' 
guidelines for the management of 
onychomycosis 2014. Br J Dermatol. 
2014;171(5):937-58.
[18] Lipner SR, Scher RK.  
Onychomycosis: Treatment and 
prevention of recurrence. J Am Acad 
Dermatol. 2019;80(4):853-67.
